Antonius Johannes Rabelink

Antonius Johannes Rabelink is a Professor of Internal Medicine (specializing in nephrology) at Leiden University Medical Center (LUMC) and heads the Department of Internal Medicine. He serves as Leiden Node Director of the Novo Nordisk Foundation for Stem Cell Medicine, reNEW, and leads the Regenerative Medicine theme under the Dutch National Science Agenda. As co-founder and Chief Scientific Officer of NecstGen (a non-for-profit GMP facility for cell/gene therapy), he drives translational research in regenerative therapies. His affiliations include:

• LUMC
• Leiden University
• RegMedXB Consortium
• EU Horizon STELLAR Consortium

His research focuses on regenerative medicine applications for kidney disease, vascular biology, and translational therapies. Key article trends include:

• Kidney regeneration and cell therapy (SPARK/ERC Grant)
• Cardiovascular complications in renal transplants
• Prenatal factors affecting vascular health

Scientific awards include the 2024 ERC Advanced Grant. He contributes to teaching Biomedical Sciences and Clinical Technology programs but no student names are listed.